AION Labs, based in Israel and a partnership of global pharma and tech firms for AI-driven drug discovery, has launched CombinAble.AI.
This new startup, born from AION’s challenge to innovate in therapeutic antibodies using AI, aims to accelerate therapeutic development through AI-enhanced antibody design.
CombinAble.AI plans to combine AI with computational simulations for biomolecules, utilizing data from AION’s pharma partners and public sources. Joining AION’s portfolio of startups like DenovAI, Promise Bio, TenAces, and OMEC.AI, CombinAble.AI further extends the venture’s commitment to advancing research and therapeutics.
“Our emphasis is on combining various advanced machine learning models, including large protein language models, molecular dynamics simulations and multi-objective optimization algorithms, integrating them into a single unified solution for targeted antibody discovery, AION Labs’ resources and expertise have been pivotal in shaping our company, providing the material and logistical support to help us refine our scientific strategy, and expand the team.
As we progress, the knowledge and insights provided by its pharmaceutical partners will be invaluable for the development and commercialization of our solution.”
— Dr. Daria Kokh cofounder and CEO of CombinAble.AI
